Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed

Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expa

Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy

Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plan

Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform

Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overwei

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analys

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic coug

NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clini

NEW HAVEN, Conn. , July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clin

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a O

B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy

Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on ben

HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clin

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologica

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintai

Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepar

Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation

HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers t

Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the ana

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cas

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of pa

NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clin

NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a cli

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clin

Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares are trading higher after the company announced the pr

Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering

US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Ha

Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winma

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clin

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the in

Trevi Therapeutics reported a smaller loss in Q4, beating analyst estimates. Share price fell 2.5%.

Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight

Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises t

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analy